Recurrent and refractory giant cell tumor of the jaw

J Craniofac Surg. 2009 Nov;20(6):2245-8. doi: 10.1097/SCS.0b013e3181bf866e.

Abstract

Recurrent giant cell tumors refractory to various treatment modalities are challenging dilemmas for the most experienced practitioner. We report a case of a multiply recurrent aggressive giant cell tumor diagnosed at 10 months of age with extensive involvement of the maxillae and mandibles unresponsive to multiple therapeutic modalities. The various treatments attempted in this patient including conventional therapies as well as the original use of bevacizumab (Avastin) are described.

Publication types

  • Case Reports

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / therapeutic use
  • Bevacizumab
  • Diphosphonates
  • Dwarfism / complications
  • Embolization, Therapeutic
  • Female
  • Giant Cell Tumors / complications
  • Giant Cell Tumors / pathology*
  • Giant Cell Tumors / surgery
  • Giant Cell Tumors / therapy*
  • Humans
  • Infant
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use
  • Jaw Neoplasms / complications
  • Jaw Neoplasms / pathology*
  • Jaw Neoplasms / surgery
  • Jaw Neoplasms / therapy*
  • Neoplasm Invasiveness
  • Neoplasm Recurrence, Local
  • Palliative Care
  • Recombinant Proteins

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Diphosphonates
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Bevacizumab